{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T06:08:51Z","timestamp":1789711731188,"version":"4.0.1"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:00:00Z","timestamp":1789689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med. Technol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>The market for drug delivery devices (DDDs), including combination products that integrate pharmaceuticals and medical devices, has expanded rapidly with the increasing use of biopharmaceuticals and growing adoption of self-administration. However, the extent and causes of approval lag and approval loss for device presentations, defined as presentations approved in one country but unavailable in the other, have not been systematically evaluated between Japan and the United States.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We analyzed approvals of biopharmaceuticals in various device presentations, including prefilled syringes (PFS), autoinjectors, multidose pen injectors, on-body injectors (OBIs), and cartridge formulations, using the Pharmaceuticals and Medical Devices Agency (PMDA) and U.S. Food and Drug Administration (FDA) databases from 2000 to 2025.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 176 biopharmaceutical products approved in the United States, 16% were not approved in Japan. However, most cases were attributable to approval loss by drug, reflecting products whose active substances were not approved for the Japanese market, rather than approval loss by device presentation. Although median approval lag tended to vary across device presentations, with multidose pen injectors and cartridge presentations showing median delays exceeding approximately two years and autoinjectors showing the shortest lag at approximately 10 months, these differences were not statistically significant. Statistical analyses using Pearson's chi-square, Fisher's exact, and Kruskal\u2013Wallis tests showed no significant differences in device presentation approval between Japan and the United States after excluding products lacking active substance approval in either country (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.961 and 0.963), or in approval lag among device presentations in Japan-first and U.S.-first products (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.088 and 0.299).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>In the United States, multiple device presentations were often approved simultaneously, whereas Japan more frequently adopted a stepwise approval approach. Differences in the regulatory scope of combination products and co-packaging requirements also contributed to country- specific packaging, potentially prolonging pre-approval preparation and increasing supply chain complexity. Overall, regulatory approval discrepancies between Japan and the United States were driven primarily by drug loss rather than device presentation loss. Accelerating drug approval, promoting simultaneous development of multiple device presentations, and enhancing regulatory harmonization for combination products may reduce approval lag by device presentation and improve patient access.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmedt.2026.1924169","type":"journal-article","created":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T05:36:16Z","timestamp":1789709776000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Approval lag and loss for biologic-device combination products in Japan and the United States"],"prefix":"10.3389","volume":"8","author":[{"given":"Makiko","family":"Mochizuki","sequence":"first","affiliation":[{"name":"Department of Regulatory Science, Graduate School of Pharmaceutical Sciences, Meiji Pharmaceutical University","place":["Tokyo, Japan"]},{"name":"MSD K.K.","place":["Tokyo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Maeda","sequence":"additional","affiliation":[{"name":"Department of Regulatory Science, Graduate School of Pharmaceutical Sciences, Meiji Pharmaceutical University","place":["Tokyo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1038\/clpt.2009.215","article-title":"Delays in new drug applications in Japan and industrial R&D strategies","volume":"87","author":"Hirai","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"B2","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1007\/s43441-024-00649-y","article-title":"Different development strategies affecting Japan\u2019s drug lag between Japan-based and foreign-based companies","volume":"58","author":"Hidaka","year":"2024","journal-title":"Ther Innov Regul Sci"},{"key":"B3","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1002\/jcph.2023","article-title":"An empirical analysis of Japan\u2019s drug development lag behind the United States","volume":"62","author":"Nakamura","year":"2022","journal-title":"J Clin Pharmacol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s43441-022-00381-5","article-title":"Potential future drug development lag in Japan based on an analysis of multiregional clinical trials in the US, Europe, and East Asia","volume":"56","author":"Noguchi","year":"2022","journal-title":"Ther Innov Regul Sci"},{"key":"B5","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1248\/bpb.b21-00898","article-title":"Lag time for new innovative, first-in-class drug approval in Japan","volume":"45","author":"Miyazaki","year":"2022","journal-title":"Biol Pharm Bull"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1007\/s00210-025-04494-0","article-title":"Consideration of the biosimilar drug lag and loss among Japan, the USA, and the EU","volume":"399","author":"Hariu","year":"2026","journal-title":"Naunyn-Schmiedebergs Arch Pharmacol"},{"key":"B7","year":"2024"},{"key":"B8","doi-asserted-by":"publisher","first-page":"79","DOI":"10.14982\/rsmp.16.79","article-title":"Analysis of factors contributing to drug lag and drug loss from an industry perspective and the need for public-private co-creation","volume":"16","author":"Sakakibara","year":"2026","journal-title":"Regul Sci Med Prod"},{"key":"B9","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1007\/s43441-024-00661-2","article-title":"Regulatory framework for drug-device combination products in the United States, Europe, and Korea","volume":"58","author":"Kim","year":"2024","journal-title":"Ther Innov Regul Sci"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.2147\/PPA.S470091","article-title":"The concizumab pen-injector is easy to use and preferred by hemophilia patients and caregivers: a usability study assessing pen-injector handling and preference","volume":"18","author":"Kahr Rasmussen","year":"2024","journal-title":"Patient Prefer Adherence"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2847","DOI":"10.2147\/PPA.S430038","article-title":"Significance of self-injectable biologics in Japanese patients with severe allergic diseases: focusing on pen-type devices and copayment","volume":"17","author":"Hanada","year":"2023","journal-title":"Patient Prefer Adherence"},{"key":"B12","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1007\/s40744-020-00245-0","article-title":"Understanding and minimising injection-site pain following subcutaneous administration of biologics: a narrative review","volume":"7","author":"St Clair-Jones","year":"2020","journal-title":"Rheumatol Ther"},{"key":"B13","year":""},{"key":"B14","year":"2024"},{"key":"B15","year":""},{"key":"B16","year":""},{"key":"B17","year":""},{"key":"B18","year":"2026"},{"key":"B19","doi-asserted-by":"publisher","first-page":"55","DOI":"10.2530\/jslsm.30.55","article-title":"Recent trends in the approval review of medical devices","volume":"30","author":"Tawaragi","year":"2009","journal-title":"J Japan Soc Laser Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"51","DOI":"10.4091\/iken.19.51","article-title":"Issues surrounding the development and review of medical devices","volume":"19","author":"Kodama","year":"2009","journal-title":"Iryo to Shakai"},{"key":"B21","doi-asserted-by":"publisher","first-page":"273","DOI":"10.4286\/jjmi.79.273","article-title":"Definition of the device lag and its measurement","volume":"79","author":"Nakano","year":"2009","journal-title":"J Jpn Med Instrum"},{"key":"B22","first-page":".","year":"2014"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1016\/S0140-6736(07)60615-1","article-title":"Japan Unveils 5-year plan to boost clinical research","volume":"369","author":"McCurry","year":"2007","journal-title":"Lancet"},{"key":"B24","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1038\/453851a","article-title":"Follow the leader","volume":"453","author":"Tsuji","year":"2008","journal-title":"Nature"},{"key":"B25","doi-asserted-by":"publisher","first-page":"59","DOI":"10.14982\/rsmp.16.59","article-title":"From drug lag to drug loss in Japan: challenges and initiatives focusing on pediatrics and rare diseases","volume":"16","author":"Sato","year":"2026","journal-title":"Regul Sci Med Prod"},{"key":"B26","first-page":"685","article-title":"Comparison of approval timing and changing process of labels of three new innovative antibody medicines originated in Japan with those of FDA and EMA","volume":"45","author":"Morimoto","year":"2018","journal-title":"Rinsho Hyoka (Clinical Evaluation)"},{"key":"B27","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1248\/yakushi.15-00224-2","article-title":"Future regulatory science through a global product development strategy to overcome the device lag","volume":"136","author":"Tsuchii","year":"2016","journal-title":"Yakugaku Zasshi"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1461460","DOI":"10.3389\/fmedt.2024.1461460","article-title":"Trends in the market for drug delivery devices categorized as combination drugs and medical devices and regulatory challenges for autoinjectors in Japan","volume":"6","author":"Mochizuki","year":"2024","journal-title":"Front Med Technol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1080\/19420862.2017.1392424","article-title":"Practical considerations in clinical strategy to support the development of injectable drug-device combination products for biologics","volume":"10","author":"Li","year":"2018","journal-title":"mAbs"},{"key":"B30","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1016\/j.xphs.2023.12.022","article-title":"A review of recent FDA-approved biologic-device combination products","volume":"113","author":"Guo","year":"2024","journal-title":"J Pharm Sci"},{"key":"B31","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41573-023-00670-0","article-title":"Overcoming barriers to patient adherence: the case for developing innovative drug delivery systems","volume":"22","author":"Baryakova","year":"2023","journal-title":"Nat Rev Drug Discovery"},{"key":"B32","doi-asserted-by":"publisher","first-page":"12","DOI":"10.11256\/jjdi.25.12","article-title":"A survey on medicine adoption and appropriate use in hospitals in 2020","volume":"25","author":"Kanai","year":"2023","journal-title":"J Pharm Inform Sci"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s41783-024-00179-w","article-title":"Recent advancements in pharmaceutical packaging and regulatory aspects","volume":"9","author":"Akram","year":"2025","journal-title":"J Packag Technol Res"},{"key":"B34","doi-asserted-by":"publisher","first-page":"4758","DOI":"10.1007\/s12325-023-02671-2","article-title":"The adherence and outcomes benefits of using a connected, reusable auto-injector for self-injecting biologics: a narrative review","volume":"40","author":"Antalfy","year":"2023","journal-title":"Adv Ther"},{"key":"B35","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1007\/s43441-021-00276-x","article-title":"New visualization models of designation pathway and group categorization of device-drug and device-biologic combination products classification in the United States: analysis of FDA capsular decisions","volume":"55","author":"Uemura","year":"2021","journal-title":"Ther Innov Regul Sci"}],"container-title":["Frontiers in Medical Technology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmedt.2026.1924169\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T05:36:18Z","timestamp":1789709778000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmedt.2026.1924169\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,18]]},"references-count":35,"alternative-id":["10.3389\/fmedt.2026.1924169"],"URL":"https:\/\/doi.org\/10.3389\/fmedt.2026.1924169","relation":{},"ISSN":["2673-3129"],"issn-type":[{"value":"2673-3129","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,18]]},"article-number":"1924169"}}